JP2022506898A5 - - Google Patents

Info

Publication number
JP2022506898A5
JP2022506898A5 JP2021525010A JP2021525010A JP2022506898A5 JP 2022506898 A5 JP2022506898 A5 JP 2022506898A5 JP 2021525010 A JP2021525010 A JP 2021525010A JP 2021525010 A JP2021525010 A JP 2021525010A JP 2022506898 A5 JP2022506898 A5 JP 2022506898A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
aryl
ring
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060775 external-priority patent/WO2020102100A1/en
Publication of JP2022506898A publication Critical patent/JP2022506898A/ja
Publication of JP2022506898A5 publication Critical patent/JP2022506898A5/ja
Pending legal-status Critical Current

Links

JP2021525010A 2018-11-13 2019-11-11 Nlrp活性に関連する状態を処置するための化合物及び組成物 Pending JP2022506898A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862760279P 2018-11-13 2018-11-13
US201862760244P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US62/760,279 2018-11-13
US62/760,248 2018-11-13
US62/760,244 2018-11-13
US201962795373P 2019-01-22 2019-01-22
US62/795,373 2019-01-22
US201962796361P 2019-01-24 2019-01-24
US201962796356P 2019-01-24 2019-01-24
US62/796,356 2019-01-24
US62/796,361 2019-01-24
PCT/US2019/060775 WO2020102100A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (2)

Publication Number Publication Date
JP2022506898A JP2022506898A (ja) 2022-01-17
JP2022506898A5 true JP2022506898A5 (cg-RX-API-DMAC7.html) 2022-11-21

Family

ID=68916531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525010A Pending JP2022506898A (ja) 2018-11-13 2019-11-11 Nlrp活性に関連する状態を処置するための化合物及び組成物

Country Status (6)

Country Link
US (1) US12134611B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880666B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022506898A (cg-RX-API-DMAC7.html)
CN (1) CN113166081A (cg-RX-API-DMAC7.html)
ES (1) ES2957692T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020102100A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN117185965B (zh) * 2023-09-18 2024-10-11 安徽金桐精细化学有限公司 一种磺酸基丙烯酸盐复配表面活性剂的制备方法
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026064385A1 (en) * 2024-09-18 2026-03-26 Ventus Therapeutics U.S., Inc. Oxadiazolone inhibitors of nlrp3 and uses thereof
CN119775202A (zh) * 2024-12-31 2025-04-08 河南旭瑞新材料科技有限公司 一种2-巯基烟酰甘氨酸的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
CA2085297A1 (en) 1991-12-20 1993-06-21 James Edward Ray Sulfonimidamides
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
PL344004A1 (en) 1998-05-05 2001-09-10 Hoffmann La Roche Pyrazole derivatives as p-38 map kinase inhibitors
CN1832928B (zh) 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
ITMI20131658A1 (it) 2013-10-08 2015-04-09 Getters Spa Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR102521955B1 (ko) 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
US11370763B2 (en) 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
PY1975819A (es) 2018-09-13 2020-04-09 Bayer Ag Derivados heterocíclicos como plaguicidas.-
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪

Similar Documents

Publication Publication Date Title
JP2022505525A5 (cg-RX-API-DMAC7.html)
JP2022507065A5 (cg-RX-API-DMAC7.html)
JP2020528889A5 (cg-RX-API-DMAC7.html)
JP2022507506A5 (cg-RX-API-DMAC7.html)
US20230174508A1 (en) Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
JP6924267B2 (ja) ピロロ[1,2−b]ピリダジン誘導体
JP6933770B2 (ja) Hivカプシド阻害剤のコリン塩形態
JP7050751B2 (ja) Nlrp活性に関連する状態を処置するための化合物および組成物
JP6662863B2 (ja) P38キナーゼ阻害剤としての4−(4−(4−フェニルウレイドナフタレン−1−イル)オキシピリジン−2−イル)アミノ安息香酸誘導体
JP2021008516A (ja) Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP6464384B2 (ja) キナーゼ阻害剤
US8338448B2 (en) Chemokine receptor modulators
JP2019519598A5 (cg-RX-API-DMAC7.html)
JP2020537657A5 (cg-RX-API-DMAC7.html)
JP2019515952A5 (cg-RX-API-DMAC7.html)
JP2021530536A (ja) インターロイキン−1活性の阻害剤としてのスルホニル尿素化合物
AU2021306755B2 (en) Immunomodulator
JP2019518071A5 (cg-RX-API-DMAC7.html)
CN112368278A (zh) Rip1抑制性化合物以及制备和使用其的方法
TW201102389A (en) Fused pyrroloprydine derivatives
TWI425945B (zh) 四氫異喹啉-1-酮衍生物或其鹽
JP2022507505A5 (cg-RX-API-DMAC7.html)
JP2018529714A (ja) Hivの処置のための化合物および組合せ物
TWI828289B (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
JP5806420B1 (ja) カルボキシメチルピペリジン誘導体